Bull case
Alpha Cognition is supported by a compelling mix of commercial traction, clinical validation, and balance-sheet flexibility, with ZUNVEYL generating ~$6M in 2Q26 revenue versus a $4.7M forecast and prescriptions rising to 2,997 monthly in June 2026, alongside 8,294 bottles dispensed and 1,908 cumulative prescribing HCPs. Its positive outlook is further reinforced by BEACON real-world evidence showing reported cognitive improvement in 92% of patients, neuropsychiatric improvement in 93%, and favorable GI tolerability, while CONVERGE and RESOLVE should deepen payer confidence and broaden adoption into long-term care and outpatient settings. Financially, the company held $41.4M in cash at the midpoint of 2026, remains guided toward cash flow break-even in late 2027, and reduced future royalty complexity through a roughly $6.1M settlement that extinguished contingent obligations.